FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2914891485> ?p ?o ?g. }

• W2914891485 abstract "Event Abstract Back to Event EFFICACY AND SAFETY OF LURASIDONE IN CHILDREN AND ADOLESCENT PATIENTS WITH BIPOLAR DEPRESSION Melissa Delbello1, Robert Goldman2, Ling Deng2, Josephine Cucchiaro2*, Andrei Pikalov2 and Antony Loebel2 1 University of Cincinnati College of Medicine, United States 2 Sunovion (United States), United States Aims: To evaluate the efficacy and safety of lurasidone in children and adolescent patients with bipolar depression. Methods: Patients ages 10-17 years of age with a DSM-IV-TR diagnosis of bipolar I depression were randomized to 6 weeks of double-blind treatment with once-daily, flexible doses of 20-80 mg. Primary and key secondary endpoints were change from baseline to week 6 in the Children Depression Rating Scale, Revised (CDRS-R) total score, and the Clinical Global Impressions, Bipolar Severity of Depression Score (CGI-BP-S-dep), respectively, evaluated by mixed model repeated measures analysis. Results: A total of 347 patients were randomized and received at least one dose of study medication: lurasidone, N=175 (mean age, 14.2 years; mean CDRS-R, 59.2; completers, 92.0%); and placebo, N=172 (mean age, 14.3 years; mean CDRS-R, 58.6; completers,89.7%). Lurasidone was associated with significant improvement at week 6 vs placebo on the CDRS-R (-21.0 vs -15.3; P<0.0001; effect size, 0.45), and on the CGI-BP-S-dep (-1.49 vs. -1.05; P<0.0001; effect size, 0.44). The 3 most frequent adverse events reported for lurasidone vs. placebo were nausea (16% vs. 6%), somnolence (11% vs. 6%), and increased weight (7% vs. 2%). Lurasidone was associated with no increases in fasting glucose or lipids; and minimal increase in mean weight vs placebo (+0.74 kg vs. +0.44 kg). Conclusions: In children and adolescents with bipolar depression, 6-weeks of placebo-controlled treatment with lurasidone (20-80 mg/d) demonstrated statistically significant and clinically meaningful improvement in measures of depression severity (CDRS-R, CGI-BP-S). In this study, lurasidone was generally well-tolerated and was associated with few effects on weight and metabolic parameters. Acknowledgements Clinicaltrials.gov identifier: NCT02046369 Sponsored by Sunovion Pharmaceuticals Inc. References Loebel, A., Cucchiaro, J., Silva, R., Kroger H., Hsu, J., Sarma, K., Sachs, G. (2014) Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 171, 160-8. doi: 10.1176/appi.ajp.2013 Ketter, T.A., Sarma, K., Silva, R., Kroger, H., Cucchiaro, J., Loebel, A. (2016) Lurasidone in the long-term treatment of patients with bipolar disorder. Depress Anxiety. 33. 424-34. doi: 10.1002/da.22479 Keywords: Major Depressive Disorder, Adolescent, atypical antipsychotics, lurasidone, randomized clinical trial, Bipolar Disorder Conference: ISAD LONDON 2017: Perspectives on Mood and Anxiety Disorders: Looking to the future, London, United Kingdom, 6 Jul - 7 Jul, 2017. Presentation Type: Oral Topic: Mood disorders in children and adolescents Citation: Delbello M, Goldman R, Deng L, Cucchiaro J, Pikalov A and Loebel A (2019). EFFICACY AND SAFETY OF LURASIDONE IN CHILDREN AND ADOLESCENT PATIENTS WITH BIPOLAR DEPRESSION. Front. Psychiatry. Conference Abstract: ISAD LONDON 2017: Perspectives on Mood and Anxiety Disorders: Looking to the future. doi: 10.3389/conf.fpsyt.2017.48.00028 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 26 May 2017; Published Online: 25 Jan 2019. * Correspondence: Dr. Josephine Cucchiaro, Sunovion (United States), Marlborough, United States, Med23577532@gmail.com Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Melissa Delbello Robert Goldman Ling Deng Josephine Cucchiaro Andrei Pikalov Antony Loebel Google Melissa Delbello Robert Goldman Ling Deng Josephine Cucchiaro Andrei Pikalov Antony Loebel Google Scholar Melissa Delbello Robert Goldman Ling Deng Josephine Cucchiaro Andrei Pikalov Antony Loebel PubMed Melissa Delbello Robert Goldman Ling Deng Josephine Cucchiaro Andrei Pikalov Antony Loebel Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page." @default.
• W2914891485 created "2019-02-21" @default.
• W2914891485 creator A5013740415 @default.
• W2914891485 creator A5014310189 @default.
• W2914891485 creator A5019090390 @default.
• W2914891485 creator A5028328307 @default.
• W2914891485 creator A5066553937 @default.
• W2914891485 creator A5079968486 @default.
• W2914891485 date "2017-01-01" @default.
• W2914891485 modified "2023-09-24" @default.
• W2914891485 title "EFFICACY AND SAFETY OF LURASIDONE IN CHILDREN AND ADOLESCENT PATIENTS WITH BIPOLAR DEPRESSION" @default.
• W2914891485 doi "https://doi.org/10.3389/conf.fpsyt.2017.48.00028" @default.
• W2914891485 hasPublicationYear "2017" @default.
• W2914891485 type Work @default.
• W2914891485 sameAs 2914891485 @default.
• W2914891485 citedByCount "1" @default.
• W2914891485 countsByYear W29148914852017 @default.
• W2914891485 crossrefType "journal-article" @default.
• W2914891485 hasAuthorship W2914891485A5013740415 @default.
• W2914891485 hasAuthorship W2914891485A5014310189 @default.
• W2914891485 hasAuthorship W2914891485A5019090390 @default.
• W2914891485 hasAuthorship W2914891485A5028328307 @default.
• W2914891485 hasAuthorship W2914891485A5066553937 @default.
• W2914891485 hasAuthorship W2914891485A5079968486 @default.
• W2914891485 hasBestOaLocation W29148914851 @default.
• W2914891485 hasConcept C118552586 @default.
• W2914891485 hasConcept C126322002 @default.
• W2914891485 hasConcept C139719470 @default.
• W2914891485 hasConcept C142724271 @default.
• W2914891485 hasConcept C162324750 @default.
• W2914891485 hasConcept C197934379 @default.
• W2914891485 hasConcept C204787440 @default.
• W2914891485 hasConcept C27081682 @default.
• W2914891485 hasConcept C2776174506 @default.
• W2914891485 hasConcept C2776412080 @default.
• W2914891485 hasConcept C2776701107 @default.
• W2914891485 hasConcept C2776867660 @default.
• W2914891485 hasConcept C2780494398 @default.
• W2914891485 hasConcept C2780580376 @default.
• W2914891485 hasConcept C2780733359 @default.
• W2914891485 hasConcept C71924100 @default.
• W2914891485 hasConceptScore W2914891485C118552586 @default.
• W2914891485 hasConceptScore W2914891485C126322002 @default.
• W2914891485 hasConceptScore W2914891485C139719470 @default.
• W2914891485 hasConceptScore W2914891485C142724271 @default.
• W2914891485 hasConceptScore W2914891485C162324750 @default.
• W2914891485 hasConceptScore W2914891485C197934379 @default.
• W2914891485 hasConceptScore W2914891485C204787440 @default.
• W2914891485 hasConceptScore W2914891485C27081682 @default.
• W2914891485 hasConceptScore W2914891485C2776174506 @default.
• W2914891485 hasConceptScore W2914891485C2776412080 @default.
• W2914891485 hasConceptScore W2914891485C2776701107 @default.
• W2914891485 hasConceptScore W2914891485C2776867660 @default.
• W2914891485 hasConceptScore W2914891485C2780494398 @default.
• W2914891485 hasConceptScore W2914891485C2780580376 @default.
• W2914891485 hasConceptScore W2914891485C2780733359 @default.
• W2914891485 hasConceptScore W2914891485C71924100 @default.
• W2914891485 hasLocation W29148914851 @default.
• W2914891485 hasOpenAccess W2914891485 @default.
• W2914891485 hasPrimaryLocation W29148914851 @default.
• W2914891485 hasRelatedWork W2035049801 @default.
• W2914891485 hasRelatedWork W2094300292 @default.
• W2914891485 hasRelatedWork W2109282245 @default.
• W2914891485 hasRelatedWork W2506929947 @default.
• W2914891485 hasRelatedWork W282266550 @default.
• W2914891485 hasRelatedWork W3172359983 @default.
• W2914891485 hasRelatedWork W4205210323 @default.
• W2914891485 hasRelatedWork W4212830572 @default.
• W2914891485 hasRelatedWork W4281811031 @default.
• W2914891485 hasRelatedWork W4306768326 @default.
• W2914891485 hasVolume "8" @default.
• W2914891485 isParatext "false" @default.
• W2914891485 isRetracted "false" @default.
• W2914891485 magId "2914891485" @default.
• W2914891485 workType "article" @default.